Business reception at the Biotechnology Innovation and Start-up Center (IZB) above the roofs of the campus
The hosts, former Minister of State Kerstin Schreyer and Dr. Peter Hanns Zobel, Managing Director of the IZB, welcomed more than 50 entrepreneurs – Keynote speech by Bertram Brossardt, managing director of the vbw –Bavarian Business Federation.
Photo caption (f. l.t.r.): Bertram Brossardt, managing director of the vbw – Bavarian Business Association, Minister of State Kerstin Schreyer (ret.), Member of the Bavarian Parliament and Chairwoman of the Committee for Economic Affairs, State Development, Energy, Digitalization and Media, Dr. Peter Hanns Zobel, managing director IZB
Munich/Martinsried, June 22, 2022 – More than 50 entrepreneurs accepted the joint invitation of Kerstin Schreyer, Member of the Bavarian Parliament and Chairwoman of the Committee for Economic Affairs, Regional Development, Energy, Digitalization and Media, and Dr. Peter Hanns Zobel, Managing Director of IZB, to a networking meeting at the Faculty Club of the Innovation and Start-up Center Biotechnology (IZB). The event took place for the ninth time on June 21, 2022, after a two-year forced break due to corona, and was fully booked.
“I am pleased that it is finally possible for us to hold events like this in presence again. It is very important that companies in the region network. After all, the contacts that are made here lead to synergies and new, joint projects,” said former Minister of State Schreyer.
“The challenges that companies have had to overcome in recent years due to the Corona pandemic and the Ukraine war are immense,” Schreyer said. During the pandemic, however, the companies based at the IZB in particular have shown great innovative strength. “It makes me very proud that so much cutting-edge technology is gathered here in my constituency at this location.” The state government is doing a great deal to ensure that this remains the case in the future. The recent go-ahead for the new Martinsried life science campus makes the site even more attractive for top international research. “This will help to create competitive jobs not only in research and development, but also in spin-offs and established biotechnology and pharmaceutical companies,” said Kerstin Schreyer.
“The biotechnology industry has been put in the spotlight during the pandemic. We will still face many medical challenges in the future and, of course, drugs are not yet available for all diseases,” explained Dr. Peter Hanns Zobel, managing director of the IZB, in his welcoming speech. “Our start-ups at IZB are working to develop innovative therapies as well as diagnostic products and bring them to market. The enormous investor interest in our start-ups shows that the cutting-edge research at IZB is highly regarded internationally. In the first half of 2022 alone, life science investors supported our start-ups with follow-up financing amounting to 170 million euros,” Zobel is pleased about the dynamics at the location.
In his keynote speech, Bertram Brossardt, managing director of the vbw –Bavarian Business Association, addressed the prospects for Bavarian industry against the backdrop of current crises and challenges. “Only a strong German and Bavarian economy can help cushion the consequences of the war for our country and support Ukraine. A gas embargo would hurt us more than Russia and lead us into recession. We therefore need to reduce our dependence on Russian gas, accelerate the shift to renewables and make longer use of existing energy sources, such as the three nuclear power plants still in operation. The “Bavarian Energy Plan” adopted by the state government is therefore the right thing to do. In parallel, it is necessary to keep labor costs under control and reduce bureaucracy. This absolutely also means a stop sign for additional burdens from Brussels,” said Brossardt.
After the speeches, an entertaining evening developed with numerous conversations. “The 2022 Business Reception was once again a complete success,” said Schreyer. A special thanks goes above all to the team at the IZB. “The Faculty Club G2B provides the ideal setting for a successful networking evening.”
The Martinsried Science Campus is one of Europe’s largest centers bringing together basic scientific research, teaching, clinical research and technology innovation. The campus is home to the Max Planck Institute of Biochemistry, the Max Planck Institute of Neurobiology, the institutes of Ludwig Maximilian University (LMU) Munich, the Helmholtz Center, the Großhadern Hospital and the Biotechnology Innovation and Start-up Center (IZB) in the immediate vicinity. This creates outstanding conditions for students and scientists, as well as strengthening the region’s economy through regular spin-offs from basic research.
Photo material from the event can be downloaded from our website:
About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
The IZB, founded in 1995, operates the innovation and start-up centers for biotechnology in Planegg-Martinsried and Freising-Weihenstephan, which has developed into a leading biotechnology center. More than 50 biotech companies with over 700 employees are currently based on 26,000 m2 of space. Here, work is being carried out on developing drugs for the most serious diseases, such as cancer, Alzheimer’s and various autoimmune diseases. A key criterion for the success of the IZBs is the physical proximity to cutting-edge research on the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt chemistry college, the two kindergartens Bio Kids and Bio Kids2, as well as the two restaurants SEVEN AND MORE and The Bowl Food Lounge are location factors that are highly valued by the company founders. Successful companies that have emerged from the IZB include Corimmun (today Janssen-Cilag), Coriolis, Exosome Diagnostics (bought by Bio-Techn), ibidi, Immunic Therapeutics, Medigene, Micromet (today Amgen), MorphoSys, Octopharma or Rigontec (now MSD). More information at www.izb-online.de
Press contact and image material requests:
Susanne Simon, Head of Press and Public Relations
Fördergesellschaft IZB mbH, Innovation and Start-up Center for Biotechnology
Am Klopferspitz 19, D-82152 Planegg-Martinsried,
Phone: +49 (0)89/55 279 48-17,